Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies.
Antineutrophil cytoplasmic autoantibodies (ANCA) are closely associated with systemic small vessel vasculitis characterized by segmental vessel wall necrotizing inflammation and a paucity of immunoglobulin deposition. Clinically, in vitro and experimental animal model observations indicate a direct pathogenic role for ANCA. This review focuses on the results of experiments utilizing a mouse model of ANCA disease induced by transfer of mouse anti-MPO IgG or anti-MPO lymphocytes into recipient mice, which causes small vessel vasculitis and glomerulonephritis that closely mimics human disease. Evidence for the following conclusion about this model, and by implication about human ANCA disease, will be summarized as follows: (1) anti-MPO IgG is sufficient even in the absence of functional T cells to cause disease and anti-MPO T lymphocytes are not sufficient to cause acute injury; (2) neutrophils are required; (3) ANCA antigens in bone marrow-derived cells are sufficient targets; (4) increased circulating pro-inflammatory cytokines and microbial products exacerbate disease, and concurrent viral infection exacerbates and modulates the phenotype of disease; (5) Fcγ receptor engagement is required for disease induction, and Fcγ receptor repertoire modulates the phenotype of disease, especially pulmonary disease; (6) activation of the alternative pathway of complement is required, complement is activated by factors released by neutrophils stimulated by ANCA IgG and engagement of C5a receptors is a primary event in complement-mediated amplification; and (7) genetic background has a marked influence on the severity and outcome of disease, and modified gene expression in bone marrow-derived cells is the primary basis for genetically determined differences in disease susceptibility. Investigations using this animal model of ANCA disease have provided important insights into the cellular, molecular and genetic factors involved in the pathogenesis of ANCA disease which are likely to lead to the identification of improved markers of disease activity and response to therapy, as well as more effective and less toxic therapies.
J Charles
JC
Jennette
Hong
H
Xiao
Ronald
R
Falk
Adil Mohamad Hussein
AMH
Gasim
D000818:Animals; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000235:genetics / Q000276:immunology / Q000503:physiopathology*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000502:physiology*; D015936:Complement C5a / Q000502:physiology; D004195:Disease Models, Animal; D005921:Glomerulonephritis / Q000235:genetics / Q000276:immunology / Q000503:physiopathology*; D016179:Granulocyte Colony-Stimulating Factor / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000502:physiology; D007377:Interleukin-3 / Q000276:immunology; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000276:immunology; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000276:immunology
D019268:Antibodies, Antineutrophil Cytoplasmic; D007074:Immunoglobulin G; D007377:Interleukin-3; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; C404145:myelopoietin; D016179:Granulocyte Colony-Stimulating Factor; D015936:Complement C5a
J Am Soc Nephrol. 2004 Aug;15(8):2103-14
15284296
Nat Med. 2008 Oct;14(10):1088-96
18836458
Am J Pathol. 2005 Jul;167(1):39-45
15972950
Curr Pharm Des. 1999 Oct;5(10):737-55
10526086
Clin Exp Immunol. 1994 Nov;98(2):270-8
7955533
Br J Pharmacol. 2007 Oct;152(4):429-48
17603557
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4115-9
2161532
Am J Kidney Dis. 2005 Apr;45(4):758-61
15806479
Am J Pathol. 2005 Jul;167(1):47-58
15972951
Annu Rev Immunol. 2008;26:513-33
18370923
Ren Fail. 1995 Mar;17(2):125-33
7644763
Blood. 1990 Jun 1;75(11):2263-4
2189509
J Leukoc Biol. 1991 Dec;50(6):539-46
1658170
J Immunol. 1994 Aug 1;153(3):1271-80
8027554
J Am Soc Nephrol. 2006 May;17(5):1235-42
16624929
J Am Soc Nephrol. 1997 Mar;8(3):386-94
9071707
J Am Soc Nephrol. 2009 Feb;20(2):289-98
19073822
Kidney Int. 2007 Apr;71(7):646-54
17299525
Transplantation. 2009 Jul 15;88(1):1-6
19584672
Am J Pathol. 2009 Apr;174(4):1212-20
19264905
J Am Soc Nephrol. 2003 Mar;14(3):661-9
12595502
N Engl J Med. 1997 Nov 20;337(21):1512-23
9366584
N Engl J Med. 1988 Jun 23;318(25):1651-7
2453802
Am J Pathol. 2007 Jan;170(1):52-64
17200182
J Am Soc Nephrol. 2006 Dec;17(12):3355-64
17108314
J Clin Invest. 2002 Oct;110(7):955-63
12370273
Kidney Int. 1992 Feb;41(2):375-83
1313124
Kidney Int. 2004 Jun;65(6):2172-83
15149330